Restasis Multidose is a drug owned by Abbvie Inc. It is protected by 10 US drug patents filed from 2016 to 2017. Out of these, 4 drug patents are active and 6 have expired. Based on its patents and exclusivities, its generic launch date is estimated to be May 11, 2034. Details of Restasis Multidose's patents and their expiration are given in the table below.

A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Restasis Multidose's patents.

Latest Legal Activities on Restasis Multidose's Patents

Given below is the list of recent legal activities going on the following patents of Restasis Multidose.

Activity	Date	Patent Number
Today's Legal Activities
Payment of Maintenance Fee, 12th Year, Large Entity	09 Apr, 2024	US8292129
Payment of Maintenance Fee, 8th Year, Large Entity	15 Apr, 2021	US8561859
Payment of Maintenance Fee, 4th Year, Large Entity	07 Dec, 2020	US9676525
Payment of Maintenance Fee, 4th Year, Large Entity	30 Nov, 2020	US9669974
Payment of Maintenance Fee, 8th Year, Large Entity	22 Apr, 2020	US8292129
Patent Issue Date Used in PTA Calculation Critical	13 Jun, 2017	US9676525
Recordation of Patent Grant Mailed Critical	13 Jun, 2017	US9676525
Patent Issue Date Used in PTA Calculation Critical	06 Jun, 2017	US9669974
Recordation of Patent Grant Mailed Critical	06 Jun, 2017	US9669974
Email Notification Critical	25 May, 2017	US9676525

While patent expiration is one way of estimating the generic date of a drug, if a patent gets invalidated somehow, the generic of the drug may arrive early. Being aware of all relevant patents can help in avoiding legal pitfalls. Given below are details of the litigation history of Restasis Multidose and ongoing litigations to help you estimate the early arrival of Restasis Multidose generic.

Restasis Multidose's Litigations

Restasis Multidose been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Jun 04, 2015, against patent number US8685930. The petitioner Apotex Corp., challenged the validity of this patent, with Allergan, Inc. as the respondent. Click below to track the latest information on how companies are challenging Restasis Multidose's patents.

Patent	Proceeding Filing Date	Status	Respondent	Petitioner
Live updates
US8629111	June, 2016	Terminated (27 Sep, 2019)	Allergan, Inc.	Mylan Pharmaceuticals Inc. et al.
US8629111	January, 2017	Terminated (27 Sep, 2019)	Allergan, Inc.	Akorn, Inc.
US8633162	June, 2016	FWD Entered (27 Sep, 2019)	Allergan, Inc.	Mylan Pharmaceuticals Inc.
US8633162	January, 2017	FWD Entered (27 Sep, 2019)	Allergan, Inc.	Teva Pharmaceuticals USA, Inc.
US8642556	June, 2016	FWD Entered (27 Sep, 2019)	Allergan, Inc.	Mylan Pharmaceuticals Inc.
US8642556	January, 2017	FWD Entered (27 Sep, 2019)	Allergan, Inc.	Akorn, Inc.
US8648048	June, 2016	Terminated (27 Sep, 2019)	Allergan, Inc.	Mylan Pharmaceuticals Inc. et al.
US8648048	January, 2017	Terminated (27 Sep, 2019)	Allergan, Inc.	Teva Pharmaceuticals USA, Inc.
US8685930	June, 2016	Terminated (27 Sep, 2019)	Allergan, Inc.	Mylan Pharmaceuticals Inc. et al.
US8685930	January, 2017	Terminated (27 Sep, 2019)	Allergan, Inc.	Akorn, Inc.
US9248191	June, 2016	Terminated (27 Sep, 2019)	Allergan, Inc.	Mylan Pharmaceuticals Inc. et al.
US9248191	January, 2017	Terminated (27 Sep, 2019)	Allergan, Inc.	Teva Pharmaceuticals USA, Inc.
US8629111	January, 2017	Terminated-Settled (06 Sep, 2017)	Allergan, Inc.	Famy Care Limited
US8633162	January, 2017	Terminated-Settled (06 Sep, 2017)	Allergan, Inc.	Famy Care Limited
US8642556	January, 2017	Terminated-Settled (06 Sep, 2017)	Allergan, Inc.	Famy Care Limited
US8648048	January, 2017	Terminated-Settled (06 Sep, 2017)	Allergan, Inc.	Famy Care Limited
US8685930	January, 2017	Terminated-Settled (06 Sep, 2017)	Allergan, Inc.	Famy Care Limited
US9248191	January, 2017	Terminated-Settled (06 Sep, 2017)	Allergan, Inc.	Famy Care Limited
US8629111	January, 2017	Terminated (31 Mar, 2017)	Allergan, Inc.	Teva Pharmaceuticals USA, Inc.
US8633162	January, 2017	FWD Entered (31 Mar, 2017)	Allergan, Inc.	Akorn, Inc.
US8642556	January, 2017	FWD Entered (31 Mar, 2017)	Allergan, Inc.	Teva Pharmaceuticals USA, Inc.
US8648048	January, 2017	Terminated (31 Mar, 2017)	Allergan, Inc.	Akorn, Inc.
US8685930	January, 2017	Terminated (31 Mar, 2017)	Allergan, Inc.	Teva Pharmaceuticals USA, Inc.
US9248191	January, 2017	Terminated (31 Mar, 2017)	Allergan, Inc.	Akorn, Inc.
US8629111	June, 2016	Terminated-Settled (08 Dec, 2016)	Allergan, Inc.	Argentum Pharmaceuticals LLC
US8629111	June, 2015	Terminated-Denied (16 Dec, 2015)	Allergan, Inc.	Apotex Corp.
US8633162	June, 2015	Terminated-Denied (16 Dec, 2015)	Allergan, Inc.	Apotex Corp.
US8642556	June, 2015	Terminated-Denied (16 Dec, 2015)	Allergan, Inc.	Apotex Corp.
US8648048	June, 2015	Terminated-Denied (16 Dec, 2015)	Allergan, Inc.	Apotex Corp.
US8685930	June, 2015	Terminated-Denied (16 Dec, 2015)	Allergan, Inc.	Apotex Corp.

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Download Report

Several oppositions have been filed on Restasis Multidose's European patents. EP oppositions can significantly impact the timeline for the generic launch of drugs. If an opposition results in the revocation or amendment of a patent, it can shorten the exclusivity period of the original drug. This can lead to an earlier entry of generic versions into the market. To help you estimate the potential early arrival of Restasis Multidose's generic, the next section provides detailed information on ongoing and past EP oppositions related to Restasis Multidose patents.

Restasis Multidose's Oppositions Filed in EPO

Restasis Multidose has faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Oct 30, 2018, by Epping Hermann Fischer Patentanwaltgesellschaft Mbh. This opposition was filed on patent number EP14815668A. Click below to reveal the latest opposition data.

Application	Filing Date	Opposition Party	Legal Status
Live updates
EP14815668A	Oct, 2018	Epping Hermann Fischer Patentanwaltgesellschaft MBH	Patent maintained as amended

US patents provide insights into the exclusivity only within the United States, but Restasis Multidose is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Restasis Multidose's family patents as well as insights into ongoing legal events on those patents.

Restasis Multidose's Family Patents

Restasis Multidose has patent protection in a total of 26 countries. It's US patent count contributes only to 26.0% of its total global patent coverage. Click below to unlock the full patent family tree for Restasis Multidose.

Full family tree

Generic Launch

About Restasis Multidose

Restasis Multidose is a drug owned by Abbvie Inc. It is used for treating dry eye by increasing tear production in patients with keratoconjunctivitis sicca. Restasis Multidose uses Cyclosporine as an active ingredient. Restasis Multidose was launched by Abbvie in 2002.